Based in Watertown, Massachusetts, Disc Medicine, Inc. operates as a clinical-stage biotechnology company. Its core mission involves the discovery, development, and commercialization of novel therapeutic solutions for individuals suffering from serious hematological diseases. The company is actively constructing a pipeline of drug candidates, designed to address a variety of these conditions by precisely targeting fundamental biological mechanisms related to red blood cell biology, particularly heme biosynthesis and iron homeostasis.
Subscribe to see Disc Medicine, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Disc Medicine, Inc. is a biotechnology company headquartered in Watertown, United States. It is publicly listed (IRON) with a market capitalisation of $2.2B. Xcout tracks 25 named people at Disc Medicine, Inc., including John D. Quisel (Chief Executive Officer, President & Director). Xcout recorded 25 job postings from Disc Medicine, Inc. in the last 90 days.
19 more named people on record for Disc Medicine, Inc., with roles, board committees and tenure — see the full roster →
Xcout recorded 25 job postings from Disc Medicine, Inc. in the last 90 days, from a hiring record Xcout has kept since June 2026.
The weekly hiring trend, the roles and locations behind it — see Disc Medicine, Inc.'s hiring signals →
A few of Disc Medicine, Inc.'s closest competitors — see the full list of competitors and alternatives →
Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology firm dedicated to transforming the treatment of blood coagulation disorders. Operating in the United States and Denmark, its mission is to enhance life and resilience for patients through innovative therapies. The company's leading pipeline candidate is HMB-001, a bispecific antibody. This asset is currently undergoing Phase 1/2 clinical trials for the preventive management of Glanzmann thrombasthenia and has progressed to Phase 2 for the prophylactic treatment of Factor VII deficiency. Additionally, Hemab is advancing HMB-002, a monovalent antibody, through Phase 1/2 clinical development. This drug is designed for the subcutaneous prophylactic treatment of Von Willebrand disease. Beyond these clinical assets, the company actively pursues numerous preclinical and discovery-stage programs. Established in 2020, Hemab Therapeutics Holdings, Inc. maintains its headquarters in Cambridge, Massachusetts.
Fulcrum Therapeutics is a biotechnology company developing new medicines aimed at transforming gene regulation to deliver treatments to patients and their families.
Scarlet Therapeutics, founded in 2021 and headquartered in Bristol, United Kingdom, is developing a pioneering platform that generates novel red blood cell-based therapeutics to treat a wide range of diseases.
Sidero Bioscience is a clinical-stage biotechnology company that develops natural iron supplement products to address iron deficiency and nutritional health. Its proprietary SideroSorb platform and BioFe iron complex utilize a unique uptake mechanism designed to improve absorption and minimize gastrointestinal side effects compared to traditional iron therapies.
Ferrosa Therapeutics AG is a Swiss biotechnology company founded in Basel, Switzerland, focusing on developing novel therapeutics to treat anemia and related conditions.
Remix Therapeutics, Inc. is a biotechnology company headquartered in Watertown, Massachusetts. The company specializes in developing novel therapies that alter RNA processing to address serious diseases.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Something wrong or missing about Disc Medicine, Inc.? Suggest a correction
Post the link and the card appears automatically — each network fetches the image itself.